Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Narcolepsy Meeting Focuses On Symptoms, But Some Urge Attention To Underlying Cause

Executive Summary

In the fourth meeting conducted under FDA’s patient-focused drug development initiative, dozens of narcoleptics talked about the symptoms they would like new therapies to address. However, some patients said new drugs should go beyond providing mere symptom relief and target the root of the condition.

You may also be interested in...



Patient-Focused Drug Development At 10: Where Does It Go From Here?

FDA may conduct more than the 20 required meetings by the end of fiscal year 2017, but how will the patient-focused drug development program find its place in helping generate new drugs?

Fibromyalgia Patient Meeting Shines Light On Lesser Known Symptoms

While pain and fatigue are well-recognized symptoms of fibromyalgia, patients testifying at the PDUFA V disease area meeting gave FDA drug review staff insight into other health effects, such as visual disturbances.

Patient-Reported Outcomes Tools Should Be Symptom Specific, FDA Says

Agency favors symptom-focused assessments over global quality-of-life evaluations when considering whether the data can support a drug labeling claim for use in treating pediatric cancer. Measures used for EU reimbursement considerations are usually not sufficient for FDA labeling claims, official cautions.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS055646

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel